“…Unlike the effectiveness only given before injury (prophylactic effect) of the standard cytoprotective agents (for review, see, i.e., [10,11]), BPC 157, in addition to its prophylactic effect, has a strong curative effect given even much later after injury induction, during ischemia as well as during reperfusion (for review, see, i.e., [2][3][4][5][6][7][8]). Illustratively, as mentioned before, in the vascular studies, as a part of the severe vascular and multiorgan failure syndrome counteraction, there was counteraction of the brain, heart, lung, liver, kidney, and gastrointestinal lesions [18,19,23,24,[27][28][29]31,[37][38][39][40]. Moreover, in other separate studies, there was counteraction of the brain [83], spinal cord [35,36], heart failure [84], lung [41,[85][86][87], liver lesions [88][89][90], liver, gastrointestinal and brain lesions [91][92][93][94][95][96], and kidney [97][98][99] and pancreas [100,101] lesions.…”